New potential of mexicor in the treatment of chronic heart failure among patients with metabolic syndrome
The study included 60 patients, aged 45-65 years, with metabolic syndrome (MS), Functional Class II-III chronic heart failure (CHF), and recent myocardial infarction (MI). The participants were randomised into 2 groups (n=30 in each). The main group received standard CHF therapy and Mexicor (0,4 g/d). The follow-up lasted for 12 weeks. In MS patients, adding a cytoprotector Mexicor to complex CHF treatment was associated with CHF FC reduction, increased exercise capacity, and greater anti-anginal and anti-ischemic effects. As a part of combined CHF therapy, Mexicor facilitated myocardial remodelling regression, also improving left ventricular diastolic function and autonomic cardiac regulation. In patients with CHF and MS, Mexicor therapy improved lipid and carbohydrate metabolism, reduced insulin resistance and chronic inflammation